Resistance to a BRAF inhibitor, the vemurafenib analogue PLX4720, was induced in four paired primary/metastatic cell lines, and, in each case, OPN expression was reduced in a manner similar to that seen in non-small-cell lung cancer [126,127]. This evidence concerns the gene SPP1 and non-small cell lung carcinoma.